Category Medicine and Healthcare
Press Release
CBD Life Sciences Inc. (CBDL) Announces President Trump Confirms Marijuana Rescheduling Is Under Consideration
"A shift to Schedule III could unlock a $30+ billion market, eliminate crippling 280E tax burdens, unleash institutional investment, and set the stage for explosive industry-wide growth." Read More
Press Release
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) Read More
Press Release
Could DEA Be Next? EPA Firings Spark Questions About DEA's Accountability in MMJ's Marijuana Licensing Delays
After the EPA dismissed employees who publicly criticized its leadership, attention is turning to the Drug Enforcement Administration's Diversion Control Division, long accused of obstructing FDA-approved cannabis research. With DEA officials Matthew Strait and Thomas Prevoznik retired and attorney Aarathi Haig facing ethical questions, patient advocates warn that new DEA Administrator Terry Cole may soon be forced to take similar disciplinary action against insiders who blocked MMJ BioPharma Cultivation's clinical trials for Huntington's disease and Multiple Sclerosis. Read More
Press Release
The Four Healthcare IT Categories Delivering the Fastest ROI in 2025 - and What's Earning a Place on the 2026 List
In the first half of 2025, 88% of boards required ROI projections for all new IT projects, and more than half of U.S. hospitals (52%) delayed or canceled initiatives with ROI timelines longer than 24 months. Read More
Press Release
Becker Plastic Surgery Discusses the Deep Plane Facelift for Treating Advanced Mid-Face and Neck Aging
Facial plastic surgeons at Becker Plastic Surgery explain how the deep plane facelift differs from traditional techniques, focusing on repositioning deeper tissues to address advanced mid-face and neck aging. Read More
Press Release
Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results
Company to host webcast today at 8.00 a.m. ET Growing portfolio of RNA delivery clients and programs Advancing plans for partial spin-off of RNA delivery activities Continued adjustment of cost structure Read More
Press Release
Brello Health Review 2025: GLP-1 Telehealth Weight Loss Program With Semaglutide, Tirzepatide, and Personalized Coaching
Learn How Brello Health's Telehealth GLP-1 Weight Loss Program Combines Semaglutide, Tirzepatide, and Expert Coaching for Safe, Sustainable Results in 2025 Read More
Press Release
MMJ Marijuana Patients' Battles Against DEA: Trump Marijuana Decision Imminent
Justice Delayed Is Justice Denied The retirement of Matthew Strait and Thomas Prevoznik is not closure-it is the beginning of a reckoning with the DEA's culture of obstruction. "Thomas Prevoznik may have pulled the trigger, but Matthew Strait loaded the gun," said Duane Boise, CEO of MMJ International Holdings. "Now the question is whether Administrator Cole will keep allowing Aarathi Haig to pull the strings, or whether he'll finally restore constitutional accountability. Patients' lives depend on it." The Seven Year Regulatory Ordeal Blocking Medical Innovation Read More
Press Release
Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases
In vitro findings reveal Telomir-1's dual action: targeting DNA methylation switches and cutting into the Wnt "fuel line" that drives cancer growth. Read More
Press Release
CBD Life Sciences Inc. (CBDL) Announces Company Will Exhibit at the NECANN Cannabis Conference in Atlantic City, NJ
NECANN New Jersey attracts over 5,000 industry leaders, features more than 200 exhibitors, and is ranked the 3rd largest B2B cannabis convention in the United States - positioning CBDL for unprecedented growth, revenue opportunities, and investor value. Read More
Press Release
Where Is The Catholic Marijuana Vote For The Patients?
Nearly 50 groups, including CatholicVote, are lobbying Trump to keep marijuana Schedule I - but where is that same passion for the patients? While faith leaders focus on fear, the DEA blocks MMJ BioPharma's FDA-approved clinical trials for Huntington's and Multiple Sclerosis, trapping science in an unconstitutional kangaroo court. This fight isn't about recreational weed - it's about whether America will allow DEA to stand between the sick and real medicine. Read More
Press Release
CLS Health's Back-to-School Campaign Provides Families With All Their Medical Needs in One Convenient Place
With 45-plus locations and more than 225 providers, the physician-owned practice makes it simpler for families to get all the appointments they need, while ensuring comprehensive, complete care. Read More
Press Release
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development program U.S. New Drug Application filing for Rusfertide in polycythemia vera on track for Q4 Read More
Press Release
Trump Holds the Rescheduling Key: Will Marijuana Reform Follow the Patient's Right to Try Path?
From ‘Right to Try' to Cannabis: Trump's Next Breakthrough Could Unlock FDA Trials. "President Trump's marijuana decision must go beyond politics-patients suffering from Huntington's disease and Multiple Sclerosis have waited nearly a decade for access to MMJ International Holdings' FDA-approved clinical trials. With capsules manufactured and science in place, all that's missing is the DEA stepping aside." stated Duane Boise, CEO MMJ International Holdings. Read More
Press Release